

Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology

July 6, 2017 4:10 PM ET

BURLINGAME, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will host an R&D Day on Tuesday, July 11, 2017, in New York City and provide a live webcast starting at 9:00 a.m. ET.

The event will focus on the adenosine pathway in immuno-oncology and its potential to address the limitations of existing agents. Speakers will include:

- **Jonathan D. Powell**, M.D., Ph.D., of Johns Hopkins University
- **Lawrence Fong**, M.D., of the University of California, San Francisco
- **Matthew Hellmann**, M.D., of Memorial Sloan Kettering Cancer Center
- **Richard Miller**, M.D., Corvus co-founder, president and CEO

R&D Day Webcast and Conference Call Details

Event Title: R&D Day Update – The Adenosine Pathway: Extending the Reach of Cancer Immunotherapy

Date: Tuesday, July 11, 2017

Time: 9:00 a.m. – 12:00 p.m. ET

Webcast: The live webcast and slide presentation can be accessed at <https://event.webcasts.com/starthere.jsp?ei=1137880>

An archive of the webcast will be available in the [Investors](#) section of the Company's website for 30 days following the event.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus' lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor's ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech's atezolizumab, an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit www.corvuspharma.com.

Tecentriq® (atezolizumab) is a registered trademark of Genentech.

Corvus Contact:

Leiv Lea

Chief Financial Officer

Corvus Pharmaceuticals, Inc.

+1-650-900-4522

LLea@corvuspharma.com

Media Contact:

Megan McCormick

Pure Communications

+1-858-617-0774

mmccormick@purecommunications.com



